Edgar Filing: INTERCEPT PHARMACEUTICALS INC - Form 4

| INTERCEP Form 4 | T PHARMACE | UTICALS | INC | | | | | | | | |
|---|--|--|----------------------------------|---|---|-----------|--------------|---|---|---|--|
| May 18, 201 | 15 | | | | | | | | | | |
| FORM | 14 INITED | | CECII | TTIES A | ND EV | | NCEO | OMMISSION | - | PROVAL | |
| | | SIAIES | | shington, | | | INGE C | OMMISSION | OMB Number: | 3235-0287 | |
| Check this box if no longer | | | | ·····B·····, | 2.0.20 | • • | | | Expires: | January 31, | |
| subject t Section Form 4 d | 6. SIAIE | Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934, Section 17(a) of the Public Utility Holding Company Act of 1935 or Section 20(b) of the Investment Company Act of 1940 | | | | | | | Estimated average burden hours per response 0.8 | | |
| Form 5 obligatio may con <i>See</i> Instr 1(b). | tinue. Section 17 | | | | | | | | | | |
| (Print or Type | Responses) | | | | | | | | | | |
| Pruzanski Mark S: | | | Symbol INTER | 2. Issuer Name and Ticker or Trading ymbol NTERCEPT HARMACEUTICALS INC [ICPT] | | | | 5. Relationship of Reporting Person(s) to Issuer (Check all applicable) | | | |
| (Last) | (First) | (Middle) | | | | inc į | | _X_ Director | 10% | Owner | |
| | . , | IC., 450 | 3. Date o (Month/I 05/14/2 | - | ansaction | | | XOfficer (give below) | | r (specify | |
| | (Street) | | 4. If Amendment, Date Original | | | | | 6. Individual or Joint/Group Filing(Check | | | |
| Filed NEW YORK, NY 10011 | | | | ed(Month/Day/Year) | | | | Applicable Line) _X_ Form filed by One Reporting Person Form filed by More than One Reporting | | | |
| | | | | | | | | Person | | | |
| (City) | (State) | (Zip) | Tab | le I - Non-E |) erivative | Secur | rities Acq | uired, Disposed of | or Beneficial | y Owned | |
| 1.Title of Security (Instr. 3) | 2. Transaction Dat (Month/Day/Year) |) Execution any | Execution Date, if | | 3. 4. Securities Acquired Transaction(A) or Disposed of (D) Code (Instr. 3, 4 and 5) (Instr. 8) (A) | | | 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) | 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) | 7. Nature of Indirect Beneficial Ownership (Instr. 4) | |
| | | | | Code V | Amount | or (D) | Price | (Instr. 3 and 4) | | | |
| Common Stock | 05/14/2015 | | | M <u>(1)</u> | 5,000 | A | \$ 8.6667 | 500,743 | D | | |
| Common Stock | 05/14/2015 | | | S <u>(1)</u> | 5,000 | D | \$ 300 | 495,743 | D | | |

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.

Edgar Filing: INTERCEPT PHARMACEUTICALS INC - Form 4

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)

| 1. Title of Derivative Security (Instr. 3) | 2. Conversion or Exercise Price of Derivative Security | 3. Transaction Date (Month/Day/Year) | 3A. Deemed Execution Date, if any (Month/Day/Year) | 4. Transactic Code (Instr. 8) | 5. Number onf Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4, and 5) | 6. Date Exercisable and Expiration Date (Month/Day/Year) | | 7. Title and Amount of Underlying Securities (Instr. 3 and 4) | |
|---|---|---|---|--|--|--|--------------------|---|--|
| | | | | Code V | (A) (D) | Date Exercisable | Expiration Date | Title | Amount or Number of Shares |
| Options to Purchase Common Stock | \$ 8.6667 | 05/14/2015 | | M <u>(1)</u> | 5,000 | (2) | 08/16/2020 | Common Stock | 5,000 |

Reporting Owners

| Reporting Owner Name / Address | | Relationships | | | | | |
|---|------------|---------------|---------|-----------------|--|--|--|
| | Director | 10% Owner | Officer | Other | | | |
| Pruzanski Mark C/O INTERCEPT PHARMACEUTICAI 450 W. 15TH STREET, SUITE 505 NEW YORK, NY 10011 | LS, INC. | X | | CEO & President | | | |
| Signatures | | | | | | | |
| /s/ Bryan Yoon, as attorney-in-fact | 05/18/2015 | 5 | | | | | |
| **Signature of Reporting Person | Date | | | | | | |

**Signature of Reporting Person

Explanation of Responses:

If the form is filed by more than one reporting person, see Instruction 4(b)(v). *

Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a). **

(1) The reported transaction was made pursuant to a Rule 10b5-1 plan adopted by the reporting person on March 27, 2015.

(2) All shares underlying this option have vested.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure. Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.